Prostate cancer drug Xtandi has been given FDA approval for ... and has advised the same course of action for patients outside of trials. The company now says patients should be advised of the ...

Citi reaffirmed its Buy rating and $13.00 price target for ORIC Pharmaceuticals (NASDAQ:ORIC), whose stock currently trades at $10.15. The company has shown strong momentum with a 25.77% year-to-date ...